Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33,647 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer.
Lv J, Zhao R, Wu D, Zheng D, Wu Z, Shi J, Wei X, Wu Q, Long Y, Lin S, Wang S, Wang Z, Li Y, Chen Y, He Q, Chen S, Yao H, Liu Z, Tang Z, Yao Y, Pei D, Liu P, Zhang X, Zhang Z, Cui S, Chen R, Li P. Lv J, et al. Among authors: li y, li p. J Hematol Oncol. 2019 Feb 18;12(1):18. doi: 10.1186/s13045-019-0704-y. J Hematol Oncol. 2019. PMID: 30777106 Free PMC article.
DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D.
Li S, Zhao R, Zheng D, Qin L, Cui Y, Li Y, Jiang Z, Zhong M, Shi J, Li M, Wang X, Tang Z, Wu Q, Long Y, Hu D, Wang S, Yao Y, Liu S, Yang LH, Zhang Z, Tang Q, Liu P, Li Y, Li P. Li S, et al. Among authors: li y, li m, li p. Mol Ther Oncolytics. 2022 Jun 6;26:15-26. doi: 10.1016/j.omto.2022.06.003. eCollection 2022 Sep 15. Mol Ther Oncolytics. 2022. PMID: 35784403 Free PMC article.
Human induced-T-to-natural killer cells have potent anti-tumour activities.
Jiang Z, Qin L, Tang Y, Liao R, Shi J, He B, Li S, Zheng D, Cui Y, Wu Q, Long Y, Yao Y, Wei Z, Hong Q, Wu Y, Mai Y, Gou S, Li X, Weinkove R, Norton S, Luo W, Feng W, Zhou H, Liu Q, Chen J, Lai L, Chen X, Pei D, Graf T, Liu X, Li Y, Liu P, Zhang Z, Li P. Jiang Z, et al. Among authors: li s, li y, li x, li p. Biomark Res. 2022 Mar 24;10(1):13. doi: 10.1186/s40364-022-00358-4. Biomark Res. 2022. PMID: 35331335 Free PMC article.
PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells.
Wei X, Lai Y, Li J, Qin L, Xu Y, Zhao R, Li B, Lin S, Wang S, Wu Q, Liang Q, Peng M, Yu F, Li Y, Zhang X, Wu Y, Liu P, Pei D, Yao Y, Li P. Wei X, et al. Among authors: li y, li j, li b, li p. Oncoimmunology. 2017 Feb 6;6(3):e1284722. doi: 10.1080/2162402X.2017.1284722. eCollection 2017. Oncoimmunology. 2017. PMID: 28405515 Free PMC article.
Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
George P, Dasyam N, Giunti G, Mester B, Bauer E, Andrews B, Perera T, Ostapowicz T, Frampton C, Li P, Ritchie D, Bollard CM, Hermans IF, Weinkove R. George P, et al. Among authors: li p. BMJ Open. 2020 Feb 9;10(2):e034629. doi: 10.1136/bmjopen-2019-034629. BMJ Open. 2020. PMID: 32041862 Free PMC article.
33,647 results
You have reached the last available page of results. Please see the User Guide for more information.